Brief: Caladrius Biosciences Announces Idmc Recommendation To Advance Clbs201 Trial For Treatment Of Diabetic Kidney Disease
19/05/2022 15:36
Caladrius Biosciences Inc CLBS.O :
* CALADRIUS BIOSCIENCES ANNOUNCES IDMC RECOMMENDATION TO
ADVANCE
CLBS201 TRIAL FOR TREATMENT OF DIABETIC KIDNEY DISEASE
* CALADRIUS BIOSCIENCES INC - NO SAFETY OR TOLERABILITY
CONCERNS
OBSERVED IN FIRST TWO PATIENTS DOSED
* CALADRIUS BIOSCIENCES INC - TOP-LINE DATA FROM ALL
SUBJECTS
EXPECTED BY Q1 OF 2023
Source text for Eikon: ID:nGNX5Dtf7j
Further company coverage: CLBS.O
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal